Please assess the completion status of the following clinical trial:

Trial Title: Oral Paricalcitol in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and older.~* First or second deceased donor or living donor renal transplant.~* Normocalcemia or hypocalcemia.~* Willing to give informed consent~Exclusion Criteria:~* Third or subsequent renal transplant.~* Incompatible blood type or positive cross-match donor.~* Multiple organ transplant recipients.~* Diabetic with plans for future pancreas or islet transplant.~* Evidence of donor-specific sensitization (positive T-cell and/or B-cell flow cytometric cross-match).~* Documented hypercalcemia (total serum calcium 10.5 mg/dl on two separate occasions) prior to transplantation.~* Serum 25(OH)vitamin D concentration ≤ 10 ng/ml

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immunosuppression without paricalcitol (control) (Type: OTHER): Subjects will receive the standard immunosuppressive therapies consisting of induction therapy with Alemtuzumab (Campath®) and Methylprednisolone (Solumedrol®), then maintained with corticosteroid avoidance using Mycophenolate Mofetil (Cellcept®) and Tacrolimus (Prograf®).
- Immunosuppression with paricalcitol (Type: ACTIVE_COMPARATOR): Subjects will receive the standard immunosuppressive therapy consisting of induction therapy with Alemtuzumab (Campath®) and Methylprednisolone (Solumedrol®), then maintained with corticosteroid avoidance using Mycophenolate Mofetil (Cellcept®) and Tacrolimus (Prograf®). In addition, subjects will receive the study medication paricalcitol (Zemplar®).

Based on this trial design, predict the completion outcome and termination type (if applicable).